# miR-1271 inhibits $\text{ER}\alpha$ expression and confers letrozole resistance in breast cancer

# SUPPLEMENTARY MATERIALS



Supplementary Figure 1: Detection of U6 snRNA in 7 pairs of BCa specimens, as presented in Figure 1A, was achieved using RT-PCR.



Supplementary Figure 2: Detection of U6 snRNA in different BCa cells, as presented in Figure 1D, was assessed using RT-PCR.



Supplementary Figure 3: Effect of PR or HER2 status on miR-1271 expression levels. (A) BT474 cells were transiently transfected with PR siRNA, HER2 siRNA and their corresponding negative controls (Ctrl siRNA), respectively. 48 h later, BT474 cells were harvested and subjected to immunoblotting analysis of ER $\alpha$  expression. (B) BT474 cells were transiently transfected with PR siRNA, HER2 siRNA and their corresponding negative controls (Ctrl siRNA), respectively. 48 h later, BT474 cells were transiently transfected with PR siRNA, HER2 siRNA and their corresponding negative controls (Ctrl siRNA), respectively. 48 h later, BT474 cells were harvested and subjected to RT-qPCR analysis of mir-1271 expression.



Supplementary Figure 4: Detection of U6 snRNA in different BCa cells, as presented in Figure 1F, was assessed using RT-PCR.



Supplementary Figure 5: Effects of letrozole treatment or androstenedione treatment on ESR1 and miR-1271 expression in MCF7 tumor xenografts. Letrozole or androstenedione-treated xenografts were collected at 14, 23 and 32 days after MCF7 cells inoculation, analyzed by RT-qPCR, and were compared with vehicle-treated xenografts collected at different timepoints (control). Letrozole treatment stimulated ESR1 expression at D 23, but exerted no effects at D 32. In contrast, androstenedione treatment, we constantly observed a significant decrease in both ESR1 and miR-1271 expression levels in the MCF7 cells transfected with miR-1271 inhibitors. These results confirm that (1) by using miR-1271 inhibitors treatment, we could suppress miR-1271 expression levels for a relatively long period of time (about 35 days); (2) miR-1271 expression appeared to be positively correlated to ESR1 expression in BCa cells. \*P<0.05 or \*\* P<0.01 when compared to the values observed in vehicle-treated xenografts at different timepoints.

## **Oncotarget, Supplementary Materials 2017**



**Supplementary Figure 6: Effect of combined treatment with miR-1271 mimic and PD98059 on** *ESR1* **or ERa expression levels. (A)** MCF7/LR cells were incubated with the MAPK pathway inhibitor PD98059 (10  $\mu$ M) for various durations, followed by RT-qPCR analysis of *ESR1* expression. **(B)** MCF7 and MCF7/LR cells were incubated with PD98059 (10  $\mu$ M) for 6 h, followed by RT-qPCR analysis of *ESR1* expression. **(C)** MCF7/LR cells were incubated with miR-1271 mimic and PD98059 for different durations, followed by immunoblotting analysis of ERa expression.



Supplementary Figure 7: RT-qPCR analysis along with *Pearson Chi-Square* test revealed that *DDIT3* mRNA level was inversely correlated with miR-1271 level in clinical BCa samples.



**Supplementary Figure 8: Effect of combined treatment with DDIT3 shRNA and PD98059 on** *ESR1* **expression levels in MCF7/LR cells.** MCF7/LR cells were transfected with DDIT3 shRNA or shRNA NC for 48 h, followed by incubation with PD98059 for another 6 h. Subsequently, the relative expression levels of *ESR1* mRNA in different experimental groups were determined using RT-qPCR.



Supplementary Figure 9: Establishment of MCF7 cells stably deficient of DDIT3 expression was confirmed using immunoblotting analysis. Ablation of endogenous DDIT3 expression significantly stimulated ERa expression levels.

#### www.impactjournals.com/oncotarget/

## **Oncotarget, Supplementary Materials 2017**



**Supplementary Figure 10: Verification of the effect of miR-1271/DDIT3/ERα cascade in another BCa luminal cell line (BT483 cells).** We transiently transfected BT483 cells with miR-1271 inhibitors or with Anti-NC as described above. 48 h later, cells were subjected to RT-qPCR (A) and immunoblotting analyses (B) to reveal the expression levels of ERα pathway and DDIT3. (C) Repression of DDIT3 expression level using shRNA treatment could effectively rescue the ERα expression levels even in the presence of miR-1271 inhibitors.

www.impactjournals.com/oncotarget/

	Number of patients (70)
Age (years)	
≤ <b>5</b> 0	31 (44.3%)
> 50	39 (55.7%)
Macroscopic tumor size	
≤ 30 mm	25 (35.7%)
> 30 mm	45 (64.3%)
Lymph node status	
$\leq$ 3 involved	41 (58.6%)
> 3 involved	29 (41.4%)
Scarff-Bloom-Richardson classification	
1	10 (14.3%)
2	17 (24.3%)
3	43 (61.4%)
Estrogen Receptor status	
Positive	43 (61.4%)
Negative	27 (38.6%)
Progesterone Receptor status	
Positive	37 (52.9%)
Negative	33 (47.1%)
HER2 status	
Positive	26 (37.1%)
Negative	44 (62.9%)

Supplementary Table 1: Characteristics of the 70 patients with primary breast cancer from Department of Breast Surgery in Liaoning Cancer Hospital & Institute (Shenyang, China)

Targets	GenBank access NO. or references	Primer sequence	Product size	Annealing Temperature	Concentration		Cycelo
					cDNA	Primer	Cycle
miR- 1271	Yang WM, <i>et al.</i> 2016	F:TTGGCACCTAGCAAGCACTCA	90	55	2 ng/µl	0.5 μΜ	40
		R: miScript universal primer (Qiagen)					
U6		F: CTCGCTTCGGCAGCACA	94				
		R: AACGCTTCACGAATTTGCGT					
ESR1	NM_000125.3	F: GTCGCCTCTAACCTCGGG	131	60			
		R: GCTTTGGTGTGGAGGGTCAT					
TFF1	NM_003225.2	F: ATACCATCGACGTCCCTCCA	106	58			
		R: TGGGACTAATCACCGTGCTG					
PGR	NM_0012024 74.3	F: TCCTCATAGGCCCAGCTCTT	117	57			
		R: TTAGTGTGGTGGCAGCTGAG					
DDIT3	NM_0011950 53.1	F: GACCTGCAAGAGGTCCTGTC	124	58			
		R: CAGTCAGCCAAGCCAGAGAA					
18S	Li W, et al. 2011	F: CTCGCCGCGCTCTACCTACCTA	120	60			
		R: ATGAGCCATTCGCAGTTTCACTGTA					
P1	NM_000125.3	F: CCAGGGCTTAAAGGTTAGGA	91	60			
		R: AAAATAGCACCCAACTGCTTCAG					
P2	NM_000125.3	F: GTCCTTCACATTTCTTTTCCTT	142				
		R: GTATCACGAGGGGGGGGGGGGGGGGGGGGGGGGGGGGGG					
Р3	NM_000125.3	F: -CATGACGCTGTGCCAGGGAG	123				
		R: TGTAACCATGAATCCCTTGT					

## Supplementary Table 2: The primer sequences used in the current study

 Yang WM, Min KH, Lee W. MiR-1271 upregulated by saturated fatty acid palmitate provokes impaired insulin signaling by repressing INSR and IRS-1 expression in HepG2 cells. *Biochem Biophys Res Commun.* 2016; 478: 1786-1791.
Li W, Wu ZQ, Zhao J, Guo SJ, Li Z, Feng X, Ma L, Zhang JS, Liu XP, Zhang YQ. Transient protection from heat-stress induced apoptotic stimulation by metastasis-associated protein 1 in pachytene spermatocytes. *PLoS One.* 2011; 6: e26013.

Antibody	Vendor	Catalog no.	Dilutions
Rabbit anti-ERa	CST (Shanghai, China)	#8644	1:1000
Rabbit anti-ERBB-2	CST (Shanghai, China)	#2165	1:1000
Rabbit anti-GRB2	CST (Shanghai, China)	#3972	1:1200
Rabbit anti-p-MAPK	CST (Shanghai, China)	#4370	1:1000
Rabbit anti-MAPK	Santa Cruz Biotechnology (Shanghai, China)	sc-292838	1:2000
Rabbit anti-p-p90RSK	CST (Shanghai, China)	#9341	1:1500
Rabbit anti-p90RSK	GeneScript (Nanjing, China)	A00603-100	1:1000
Rabbit anti-β-ACTIN	Thermo Fisher Scientific (Shanghai, China)	PA1-46296	1:3000
Mouse anti-DDIT3	Abcam, (Hangzhou, China)	ab11419	1:500 (IB) 2µg/reaction (IP)
Goat anti-Rabbit IgG-HRP secondary antibody	Abcam, (Hangzhou, China)	ab97200	1:10000
Goat anti-Mouse IgG-HRP secondary antibody	Santa Cruz Biotechnology (Shanghai, China)	sc-2005	1:2500

# Supplementary Table 3: Sources of antibodies and the working dilutions that were used in the current study